Current and Resolved Drug Shortages and Discontinuations Reported to FDA
Report a Drug Shortage |
Contact Us |
FAQ |
Background Info |
Get Email Alerts |
Download Current Drug Shortages
Start Over | Back to Previous Screen
Azacitidine for Injection
Status: Currently in Shortage
»Date first posted:
12/18/2020
»Therapeutic Categories: Oncology
Accord Healthcare Inc. (Revised 06/10/2021)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 100 mg per vial (NDC 16729-306-10) | Limited availability. | Shortage of an active ingredient |
Armas Pharmaceuticals Inc (Revised 01/04/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 100 mg per vial (NDC 72485-201-01) | Available |
Breckenridge Pharmaceutical (Revised 01/13/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 100 mg per vial (NDC 51991-797-98) | Unavailable | No longer marketed. Expiry of last lot marketed: 01/31/2024 | Discontinue of manufacture of drug for distribution in Breckenridge label |
Celgene Corporation (Revised 10/01/2021)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 100 mg single-dose vial in cartons of 1 vial, (NDC 0781-3253-94) | Available | ||
| 100 mg single-dose vial in cartons of 1 vial, (NDC 0781-9253-94) | Available | ||
| VIDAZA, , 100 mg single-dose vial in cartons of 1 vial, (NDC 59572-102-01) | Available |
Cipla Limited (Revised 06/08/2021)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 100 mg per vial (NDC 69097-805-40) | Available | Demand increase for the drug |
Dr. Reddy's Laboratories, Inc. (Reverified 01/24/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 100 mg per vial, (NDC 43598-305-62) | Available |
Eugia Pharma Specialties LTD. (formerly Aurobindo) (Reverified 03/17/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 100mg/vial (NDC 55150-393-01) | Available | Check wholesalers for inventory |
Fresenius Kabi USA, LLC (Reverified 03/31/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 100 mg per vial, single dose vial, PF, (NDC 63323-771-39) | Available | Demand increase for the drug |
Hikma Pharmaceuticals USA, Inc. (formerly West-Ward) (Revised 10/13/2022)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 100 mg per vial, (NDC 0143-9606-01) | Inventory is currently available. | Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released. | Demand increase for the drug |
Meitheal Pharmaceuticals, Inc. (Reverified 02/13/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 100 mg per vial (NDC 71288-115-30) | Available |
Mylan Institutional, a Viatris company (Reverified 03/28/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 100 mg per vial (NDC 67457-254-30) | Presentation discontinued |
Teva Pharmaceuticals (Reverified 03/21/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 100 mg/vial Lyophilized Powder (NDC 68001-0313-56) | MADE TO ORDER PRODUCT | Product is manufactured and labeled for Blue Point Laboratories on a made to order basis |